HHS Public Access
Author manuscript
Author Manuscript

Ther Deliv. Author manuscript; available in PMC 2015 June 02.
Published in final edited form as:
Ther Deliv. 2014 November ; 5(11): 1191–1201. doi:10.4155/tde.14.79.

Biodistribution of PLGA and PLGA/chitosan nanoparticles after
repeat-dose oral delivery in F344 rats for 7 days
Sara M Navarro1, Caleb Darensbourg1, Linda Cross1, Rhett Stout2, Diana Coulon3, Carlos
E Astete1, Timothy Morgan4, and Cristina M Sabliov*,1
1Biological

& Agricultural Engineering Department, LSU & LSU AgCenter, Baton Rouge, LA, USA

Author Manuscript

2Pathobiological

Sciences, School of Veterinary Medicine, Louisiana State University, Baton

Rouge, LA, USA
3LSU

AgCenter

4Pathobiology

& Population Medicine, College of Veterinary Medicine, Mississippi State
University, MS, USA

Abstract
Aim—To quantify in vivo the biodistribution of poly(lactic-co-glycolic) acid (PLGA) and PLGA/
chitosan nanoparticles (PLGA/Chi NPs) and assess if the positive charge of chitosan significantly
enhances nanoparticle absorption in the GI tract.
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Material & methods—PLGA and PLGA/Chi NPs covalently linked to tetramethylrhodamine-5isothiocyanate (TRITC) were orally administered to F344 rats for 7 days, and the biodistribution
of fluorescent NPs was analyzed in different organs.
Results—The highest amount of particles (% total dose/g) was detected for both treatments in
the spleen, followed by intestine and kidney, and then by liver, lung, heart and brain, with no
significant difference between PLGA and PLGA/Chi NPs.
Conclusion—Only a small percentage of orally delivered NPs was detected in the analyzed
organs. The positive charge conferred by chitosan was not sufficient to improve the absorption of
the PLGA/Chi NPs over that of PLGA NPs.

Background
Author Manuscript

Oral administration of drugs faces several limitations including degradation under the acidic
environment of the stomach and enzymatic degradation, as well as low intestinal mucosal
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permeability and rapid clearance of unabsorbed drugs from the GI tract [1–3]. Recently,
attention has been focused on polymeric nanoparticles (NPs) as a way to efficiently deliver
drugs that are susceptible to gastrointestinal degradation, or are poorly absorbed [4,5].
NP composition affects drug behavior in vivo, and hence the pharmacokinetics and efficacy
of the entrapped drug. Several polymers have been extensively studied as viable materials
for NP drug delivery systems. Poly(lactic-co-glycolic) acid (PLGA) is a biodegradable and
biocompatible polymer shown to adequately entrap and deliver hydrophobic and hydrophilic
molecules [6] for improved drug bioavailability and efficacy [7]. Chitosan, an Ndeacetylated derivative of chitin, is regarded as a non-toxic, biocompatible, positively
charged polymer. In vitro and in vivo studies suggested that absorption of drugs can be
improved by chitosan due to a combination of enhanced mucoadhesion and transient
opening of tight junctions between the mucosal cells [8].
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NP size, hydrophobicity and charge have been shown to play a critical role in the uptake of
NPs delivered orally to mice and rats [9]. According to Primard et al. [10], NPs must be less
than 200 nm to diffuse through the mucus and avoid elimination by mucilliary clearance
after oral delivery. The surfactant used in the NP preparation affects the size and
hydrophobicity [11], thereby affecting NP uptake [12]. Particles that are less hydrophilic are
more readily absorbed than those covered with poly(vinylalcohol) (PVA), suggesting that
surface hydrophobicity plays a major role in the uptake of orally delivered particles [11].
Positively charged chitosan particles are trapped within the negatively charged mucin layer
immediately adjacent to the intestinal epithelium, leading to increased epithelial contact time
and thereby increasing absorption of the entrapped drug [13,14].
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NP tracking during their transit from the GI tract to major organs is most commonly
measured by radioactive labeling [15,16], or fluorescent labeling with FITC [4], rhodamine,
coumarin [17] or rhodamine B isothiocyanate (RBITC) [18]. Biodistribution results are
reported either as percentage fluorescence or percentage radioactivity detected in different
organs at a certain time point relative to total fluorescence/radioactivity at that time, as
percentage dose relative to the total administered dose, or as percentage dose per gram tissue
at each time point. Other authors had expressed the results as percentage particles detected
in tissue [19]. These differences in reporting must be considered when comparing the
literature on NP uptake and biodistribution [20]. In addition, most of the in vivo studies test
the NPs biodistribution after administration of a single dose of NPs. There is a paucity of
literature in which NP distribution was quantified following a repeat-dose exposure,
particularly oral exposure. Most in vivo biodistribution data is reported for NPs delivered
intravenously. When the intravenous route is used, the liver concentrates the highest
percentage of dose after 24 h [15], but when NPs are orally administered, results can vary
depending of the nature of the NPs [11].
The aim of this study was to quantify biodistribution of PLGA and PLGA NPs covered with
a layer of chitosan (PLGA/Chi) of similar sizes and surfactant concentrations, and to test
whether the presence of positively charged chitosan significantly improved the
gastrointestinal uptake of the NPs. It was hypothesized that PLGA/Chi NPs will have better
absorption through the gut due to their charge, but once absorbed, relative distribution
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within rat tissues compared with neutral charged NPs (PLGA) would be similar.
Tetramethylrhodamine-5-isothiocyanate (TRITC) covalently labeled PLGA and PLGA/Chi
NPs were synthesized to allow for the NPs to be traced in each tissue via fluorescence. After
daily oral administration of 3 mg NPs for 7 days to F344 rats, a comparison between the
biodistribution of PLGA and PLGA/Chi NPs in various tissues, including intestine, liver,
spleen, kidney, lung and brain, was performed.

Materials & methods
Materials
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Synthesis of TRITC-labeled PLGA—The attachment of TRITC to PLGA was
performed by uranium salt chemistry [21,22]. Briefly, 1 g of poly (D, L-lactide-co-glycolide)
(PLGA) was dissolved in 20 ml of DCM at room temperature (Figure 1). Next, 52.5 mg of
HATU, 23.4 mg of N-Boc-ethylenediamine, and 0.20 ml of DIPEA was added. The
suspension was stirred for 12 h at room temperature. The reaction was stopped by addition
of 100 ml of distilled water. Next, the organic solution was poured in 150 ml of ethanol to
obtain a white precipitate (1) that was collected by filtration. The washing protocol was
repeated twice, and the final solids were dried under high vacuum overnight. Next, a
deprotection step was performed on the 800 mg solids recovered from the previous step by
re-suspending the intermediate product in 10 ml of DCM, followed by the addition of
trifluoroacetic acid (TFA) (1:1 DMC:TFA v/v). The reaction was carried out for 35 min at
room temperature under mild stirring. Next, the solution was added drop-wise to 100 ml of
ethanol. The precipitated polymer (2) was dried under high vacuum overnight. The solids
were suspended in 10 ml of DCM, and 1 ml of triethanolamine (TEA) was added for
neutralization. The mixture was added drop-wise to 100 ml of ethanol, and the white
precipitate was dried again under high vacuum overnight. The final step was the conjugation
of PLGA amine to TRITC, which was performed by dissolution of PLGA-amine polymer
(700 mg) in 20 ml of DCM and 0.065 ml of DIPEA. After 10 min of mixing at room
temperature, 20 mg of TRITC was added. The reaction was carried out under stirring
overnight at room temperature under dark conditions. The organic phase was washed with
water six to nine times in a separation funnel. The organic phase was poured into 100 ml of
ethanol to obtain a dark pink solid precipitate. The solids (3) were collected by filtration and
re-suspended in 20 ml of DCM for another ethanol precipitation step. Finally, the solids
were dried under high vacuum for 30 h and kept at −20°C for further characterization and
use in polymeric NP synthesis.
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PLGA, PLGA-TRITC & PLGA/Chi NP synthesis—The polymeric NPs were
synthesized by emulsion evaporation technique [23,24]. The organic phase was formed by
ethyl acetate (10 ml) with dissolved PLGA (200 mg) and PLGA conjugated with TRITC
(300 mg). Next, 80 ml of the aqueous phase with polyvinyl alcohol (2% w/v) was saturated
with ethyl acetate. The organic phase was poured into the aqueous phase and mixed for 10
min at room temperature. The emulsion was microfluidized (Microfluidics, Newton, MA,
USA) at 30,000 Psi. Next, the solvent was evaporated under vacuum for 1 h with a
rotoevaporator (Buchi Corporation, New Castle, DE, USA). The purification was performed
by dialysis (molecular weight cut-off 100,000 g/mol) with regenerated cellulose membranes
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(Spectrum Laboratories, Rancho Dominguez, CA, USA) for 2 days. For PLGA/Chi NP
synthesis a chitosan solution (5% of the initial mass of PLGA) at pH 5 was added to PLGA
NPs suspension following dialysis, and the final suspension was stirred for 15 min at room
temperature. The ionic interactions between the negative charge of PLGA carboxylic acid
end groups and the positive amine groups of chitosan allowed a layer formation at the
interface of the polymeric NPs. Finally, trehalose (1:1 w/w) was added as cryoprotectant to
the NP suspension before freezing the sample. A Freeze drier (Labconco, Kansas City, MO,
USA) was used to dry the polymeric NPs for 2 days. The final powder was stored at 4°C for
characterization and animal studies.
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Residual PVA measurement—The colorimetric method used to quantify residual PVA
on the surface of the NPs was based on the reaction of iodine and the hydroxyl groups of
PVA [25]. Briefly, the sample was dissolved in 2 ml of NaOH (1 N) and heated to 60°C for
15 min, followed by a pH adjustment with 0.9 ml of 1 N HCl and 2.1 ml of distilled water.
Next, 3 ml of boric acid (0.65 M), and 0.5 ml of iodine/KI solution (0.05 M/0.15 M) were
added. The final volume was adjusted to 10 ml with distilled water. Finally, after 15 min at
room temperature, the samples were read at 690 nm with a spectrophotometer (Genesis 6,
Thermo Scientific, Asheville, NC, USA). The standard curve was prepared with the same
protocol using different PVA concentrations (2–20 μg/ml).
Characterization of fluorescent NPs
Size measurements of particles & ζ potential—Malvern Zetasizer Nano ZS was
used (Malvern Instrument Ltd., Worcestershire, UK) to measure NP size, size distribution
and ζ potential. ζ potential was measured in 10 mM NaCl at different pHs; a concentration
of 100 μg/ml of particle powder was used for size and ζ potential measurements.
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Morphology—Transmission electron microscopy pictures were taken with a JEOL 100CX (Jeol USA Inc., Peabody, MA, USA). The NP powder was re-suspended in water, and a
sample droplet was placed on a carbon grid and uracyl acetate (2%) added as contrast agent.
The excess was removed with a filter paper and the sample was dried for 10 to 15 min at
room temperature before placing the grid in the transmission electron microscope.
In vivo biodistribution of fluorescently labeled PLGA & PLGA/Chi NPs
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Animals—Male F344 rats (200–300 g) were used for the in vivo biodistribution studies.
Animals used in the experiment were all maintained, treated and housed according to the
guidelines of the Louisiana State University Institutional Animal Care and Use Committee.
The animals were acclimated for 1 week before the treatment, and randomly divided into
groups of two rats per cage. The animals were gavaged once daily for 7 days with a dose of
3mg/ml of PLGA and PLGA/Chi NPs, respectively (~12 mg/kg, depending on the weight of
the animal). All rats were fasted for 12 h before the gavage, but allowed free access to water.
Two different NPs were used as treatments: PLGA NPs and PLGA/Chitosan NPs, both
fluorescently tagged. NPs were suspended in Phosphate Buffer Saline (pH 7.4) prior to
gavage. Each treatment was orally administered to four rats (1 ml of suspended NPs/rat).
Three similarly housed but untreated rats (without polymeric NPs) were used as a control.
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The same control rats were euthanized after quarantine and the tissues were used to prepare
the fluorescent standard curves used to detect NPs in the treated animals.
Tissue collection—After 7 days of daily gavage the animals were euthanized by CO2
asphyxiation followed by cervical dislocation. Euthanasia was performed 24 h after the last
gavage. Gross necropsies were performed, and heart, spleen, kidney, liver, intestine and
brain were excised for further analysis. The samples were stored at −80°C until use.

Author Manuscript

Biodistribution analysis—Four rats per type of particles were used to measure NP
biodistribution. The tissues were homogenized in PBS, using an IKA ULTRA-TURRAX
homogenizer model T18 basic (IKA® Works Inc., Wilmington, NC, USA), and then
completely digested in 1 N NaOH following a procedure adapted from Yin et al. [4]. After
centrifugation at 7155 g for 10 min at room temperature, 100 μl of the supernatant was
loaded in triplicate in black 96 wells plate with clear bottom, and the fluorescence intensity
was measured using a Perkin Elmer Wallac 1420 multilabel counter (software version 3.0)
(Perkin Elmer, Waltham, MA, USA). To set up the calibration curves, increasing amounts of
fluorescent NPs were added to each tissue type recovered from the control animals.
Following digestion, the samples were centrifuged, and the fluorescence intensity measured
as previously described. The standard curves were developed separately for each tissue (R2
of 0.99 for standard curves developed for tested tissues). A known amount of tissue was
collected from three control animals and an increased amount of NPs was added to each
tissue, separately. Every sample was read in triplicate and the corresponding plots included
the nine measurements, per each concentration (three replicates collected in tissues from
three animals) at five concentrations. The amount of NPs distributed in each tissue was
calculated based on the standard curves and expressed as percentage total dose per gram
tissue. The percentage of dose in every tissue was calculated by dividing the NP
concentration (mg/ml) obtained from the standard curves at the fluorescence measured in the
sample to the total administered NP dose.
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Statistical analysis—The statistical analysis was performed in SAS (Cary, NC, USA).
Anova PROC MIXED procedure with Tukey adjustment and the macro by Arnold Saxton
was used for post hoc adjustment to detect differences between treatments. A significant
difference was declared at p values <0.05. The data presented residuals with a normal
distribution (p > 0.05); homogeneity and independence was confirmed.

Results
Particle characterization
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PLGA and PLGA/Chi NPs measured in average 112 and 134 nm in diameter (Table 1),
respectively. Polydispersity index (PDI) indicated that PLGA NPs (PDI of 0.112) were more
tightly distributed than PLGA/Chi NPs (PDI of 0.25). The amount of PVA present on the
surface of the particles was maintained at equal values between the two types of particles
tested, at 23–24%. PLGA NPs were negatively charged (ζ potential of −2.1 mV), whereas
PLGA/Chi NPs were positively charged (ζ potential >0 mV) up to pH 8.5 in the presence of
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10 mM NaCl. All particles were spherical in shape and showed little agglomeration (Figure
2).
The pH titration data showed that PLGA NPs were stable in the pH range tested (1.8 to 8.7)
with uniform particle diameter (100–110 nm) and negative ζ potential (0 ± 3 mV; Figure 3).
PLGA/Chi NPs measured 140–150 nm at pHs ≤6, followed by an increase in the particle
diameters at higher pH (480 nm at pH 8.7). ζ potential of PLGA/Chi NPs constantly
decreased from 33 mV at pH 2 to 1 mV at pH 8.7.
In vivo biodistribution of NPs
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Biodistribution of fluorescent NP in each tissue was determined based on the established
standard curves, and the results were expressed as percentage dose per gram tissue tissue to
compensate for possible variations between animals. The percentages were calculated
relative to the total dose (21 mg of NPs over a 7 day period) (Figure 4).
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The relative NP biodistribution in various organs indicated that the highest amount of PLGA
NPs concentrated in the spleen (0.6% total dose/g), followed by kidney (0.3% total dose/g),
intestine (0.28% total dose/g), lung (0.17% total dose/g), liver (0.14% total dose/g), brain
(0.08% total dose/g) and heart (0.03% total dose/g). The concentration of PLGA/Chi NPs
recovered in tested tissue was the following: spleen (0.63% total dose/g), kidney (0.39%
total dose/g), intestine (0.32% total dose/g), lung (0.21% total dose/g), heart (0.10% total
dose/g), brain (0.08% total dose/g) and liver (0.02% total dose/g). For both PLGA and
PLGA/Chi NPs, the biodistribution of NPs showed three statistically different groups: the
highest represented by the spleen, followed by intestine and kidney, and then by lung, brain,
heart and liver (Figure 4). Statistically, the difference between PLGA and PLGA/Chi NPs
was not significant.
The percentage NPs recovered in each organ was calculated by multiplying the percentage
of daily or total dose per gram of tissue with the individual organ weight recorded for each
individual animal. Overall, 6.6% PLGA and 5.9% PLGA/Chi of total dose were recovered
after 7 days of daily gavage with 3 mg NPs/dose in the tissue processed (Figure 5). The
percentage of the total PLGA NP dose recovered was highest in the intestine (3.34%) and
was followed by the liver (1.63%), kidney (0.79%), spleen (0.36%), lung (0.29%), brain
(0.15%) and heart (0.03%). The percentage of total PLGA/Chi NP dose demonstrated a
similar distribution (Figure 5).
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The total mass of NPs recovered (mg) at the end of the study in the assessed organs was
approximately 1.38 mg for PLGA and 1.23 mg for PLGA/Chi of the total 21 mg
administered over the 7-day study. Intestine showed the highest amount of recovered
particles in comparison with the other organs, which is not surprising for an oral delivery
system, but no significant difference was found between PLGA and PLGA/Chi NPs (Figure
6).
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Discussion
In this study, PLGA and PLGA/Chi NPs were investigated to determine the effect of NP
charge on uptake and biodistribution of NPs orally delivered to rats in a repeat-dose study.
PLGA used in the NPs synthesis was covalently linked to a fluorescent dye (TRITC), which
allowed NP tracking and quantification in all organs of interest. Particles tested were similar
in size (112 nm vs. 134 nm in diameter for PLGA and PLGA/Chi NPs), and had a similar
amount of surfactant on the surface (24%). ζ potential of PLGA NPs was slightly negative
(−1.5 mV), whereas PLGA/Chi NPs had a slight positive ζ potential ranging from of +1.8
mV to +4.9 mV in presence of 10 mM NaCl measured by titration (Figure 2) or by capillary
cell (Table 1) at neutral pH.
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Even though nanoparticle absorption was expected to be improved for the positively charged
particles, PLGA/Chi results showed a small increment in uptake compared with PLGA NPs
after 7 days of daily gavage with no statistically difference between the two types of NPs.
Chitosan is strongly charged at acidic pHs due to the protonation of the amine groups [14].
If protonated, the strong positive charge of chitosan promotes ionic interaction between the
NPs and the mucus in the gut (i.e., mucin has negatively charged carboxylic end groups at
neutral pHs) [26]. The electrostatic interaction between negatively charged mucus and
positively charged PLGA/Chi NPs would extend the retention time of NPs in the gut [27]
and as a result improve NP absorption [13]. The small improvement observed in polymeric
NP translocation when covered with a layer of chitosan (Figure 6) was most likely due to the
charge screening effect of the polymeric surfactant, PVA present on the NP surface. PLGA
and PLGA/Chi NPs ζ potentials albeit one negative (−1.5 mV) and the other positive (+1.8
mV), were very close to neutral under the pHs representative of the intestine (Figure 3),
resulting in no significant difference between the systems in terms of NP uptake. The overall
recovery of polymeric NPs after 7 days of daily gavage was around 6.6% for PLGA NPs and
5.9% for PLGA/Chi NPs of the total gavaged dose of 21 mg. Since metabolism and
excretion of absorbed NPs was occurring throughout the study, the 1.4 mg recovered at the
endpoint likely represents the steady state concentration of particles. The low absorption for
an orally administered NP treatment was not surprising. Other studies of PLGA NP
translocation in animal models have shown high excretion of NPs. For example, Le Ray and
coworkers [15] measured the percentage of radioactive NPs in feces and urine after 24 h of
oral administration of NPs and found them to be equal to 65.5 ± 32.5% and 0.3 ± 0.2%,
respectively. Similar results were found by Loeschner study [28] that showed Ag NP
recovered in feces and urine was 63 ± 23% and 0.005 ± 0.003%, respectively.
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For all orally delivered NPs, it is expected that a high percentage of the NPs would be
detected in the intestine. It has been shown that the highest percentage of 146 ± 10.1 nm
covalently linked FITC-PLGA NPs and 239 ± 13.6 nm PLGA conjugated to wheat germ
agglutinin WGA-PLGA NPs were found in the intestine following gavage of rats for 7 days
[4]. Florence and Hussain [29] reported that transit time from the stomach to the colon in
normal rat gut was 24 h. Using I125 labeled PLGA NPs (200 nm), they showed that at 4 h,
30% of the total dose was in the small intestine, and at 8 h around 40% of total dose was in
caecum. Quini et al. [30] compared the transit time of liquid and solid meals in rats using a
non-invasive magnetic method and found that 7 h after feeding the gastric section was
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completely empty of solid meal. In the present study, samples were collected 24 h after the
last dose was administered, and we expected that some of the NPs had already passed in the
feces, while others were either in tissue or in circulation, hence the relatively low amount of
particles detected in the intestine. When compared with other tissues of interest, the presence
of particles in the intestine (3.5%) was higher than in other organs, with liver, kidney and
spleen following closely.
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The administration, distribution, metabolism and excretion (ADME) process of intravenous
and oral delivery NPs had been discussed in the literature [31,32]. The distribution of NPs
has been shown to be affected by the size, shape, surface charge and mechanical properties
[33,34]. In comparison, NPs orally administered need to pass several barriers on their way to
systemic circulation, such as the acidic pH in the stomach, proteases in the gut lumen and
brush border membrane, tight junctions between enterocytes and metabolism by liver
enzymes [33], and mucus barrier along GI tract [35]. Orally administered NPs cross the
intestinal epithelial cells primarily by transcytosis [33]. Once endocytosed, NPs present in
the lamina propria have the option of being transported to distant tissues via blood or the
lymphatics [36]. Typically, water soluble substances move quickly into the vasculature
while lipophilic compounds move into and through the lymphatics prior to entering the
circulation [36–38]. Based on the fact that polymeric NPs tested in this study were water
soluble, they probably followed the blood vascular route from the intestine to the other
target organs tested.
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In this study, the reported biodistribution of NPs of different surface properties showed the
highest percentage total dose of NP/g recovered in the spleen (0.56% per gram PLGA –
0.63% per gram PLGA/Chi). Similar high uptake of NPs by the spleen was previously
reported [39], for orally administered fullerene for 7 consecutive days (daily dose of 1.7
mg/kg body weight). The spleen is a secondary lymphoid organ present in all the vertebrates
and has three main functions. First, T- and B-lymphocytes in the splenic white pulp rapidly
produce immune-mediated responses to antigens carried by the blood. Second, the splenic
red pulp has a filtering function for the blood (material can be phagocytized by
macrophages) and third, in some mammalian species it can be a reservoir of red blood cells
[40]. When the NPs reach the systemic circulation, the particles can potentially interact with
plasma proteins, coagulation factors, and blood cells [32]. It is plausible that circulating NPs
interacted with plasma proteins or cellular blood components and were removed from the
systemic circulation by the resident macrophage population in the spleen, leading to the high
splenic concentration of particles.
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Kidneys had the second highest concentration (0.4% total dose/g) for both types of NPs
(PLGA and PLGA/Chi). Renal clearance of intravascular agents is a multifaceted process
involving glomerular filtration, tubular secretion, and finally elimination of the molecule
through urinary excretion. As intravascular agents enter the glomeruli, molecules are either
filtered through the glomerular capillary wall and into the proximal tube, or remain within
the vascular compartment [41]. Due to the possibility that intact particles or small parts of
the fluorescently-tagged NPs might have been dislocated during the process of NP
degradation, their presence in the kidney was not surprising.
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The hepatobiliary system represents the primary route of excretion for particles that do not
undergo renal clearance. The liver provides the critical function of catabolism and biliary
excretion of bloodborne particles as well as serves as an important site for the elimination of
foreign substances and particles through phagocytosis. The liver is a large organ and
therefore the recovered NP dose (% dose/g tissue) appeared small, but when compared with
the other smaller organs the overall amount of particles in the liver (mg) was in fact
significant.
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The lung recovered only 0.17% and 0.21% of total dose/g of PLGA and PLGA/Chi NPs,
respectively, as a result of the uptake of the NPs that entered the blood circulation into the
lungs. The brain and heart reported less than 0.1% per gram each of the total percentage of
dose of administered NPs. The small NP concentration in the heart was expected
considering that the heart is not as highly perfused (on a ml or volume basis) when
compared with the other larger organs (liver, intestines, spleen), and it is not a filter organ
like the liver, kidney, and spleen. The small NP uptake by the brain indicated that very small
amounts of NPs if any make it through the blood–brain barrier.

Conclusion

Author Manuscript

The small positive charge of chitosan was not sufficient to significantly increase the
absorption of the charged NPs. After seven days of repeated daily gavage no significant
difference in absorption was found between PLGA and PLGA/Chi NPs, mostly due to the
charge-shielding effect of the polymeric surfactant used on the surface of the particles. NP
biodistribution data indicated that the spleen had the highest concentration of NPs when
expressed as percentage dose per gram tissue, whereas the intestine packed the highest
amount of particles, followed by the liver when the concentration was expressed as
percentage dose. The total amount of particles recovered after seven days was less than 1.5
mg of the 3 mg NPs administered daily for 7 days (for a total of 21 mg), so most particles
were either not absorbed, circulating in the blood or were excreted from the system
indicating that bioaccumulation was not occurring to any significant degree. Additional
studies are needed to determine the percentage absorption and the half-life of the NPs.

Future perspective
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Just as with any other oral delivery system, polymeric NPs need to be meticulously studied
to understand their potential for different drug delivery applications. Due to the enormous
number of options for polymers, surfactants, and drugs, the task of assessing biodistribution,
metabolism and excretion of all individual nanodelivery systems is tremendous. The in vivo
study conducted herein is simply the first step in identifying the ADME process for the types
of NPs tested. With knowledge on biodistribution of NPs and their overall intestinal uptake,
the effect of the NP presence in various organs on the function of the organ and overall
toxicity of the nanodelivery systems must be studied. Acute and repeat-dose studies are
necessary to deem NPs safe to use as oral delivery systems.
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Key terms
Polymeric nanoparticles: Nanoparticles made of polymers measuring between 1 and 100
nm in diameter.
Biodistribution: Method of tracking where compounds of interest travel in an
experimental animal or human subject.
Gavage: The administration of food or drugs, especially to an animal, typically through a
tube leading down the throat to the stomach.
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Key term
Fluorescence: The property of absorbing light of short wavelength, such as ultraviolet
light, and emitting light of longer wavelength.
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Key term
GI tract: Organ system responsible for consuming and digesting foodstuffs, absorbing
nutrients, and expelling waste, commonly defined as the stomach and intestine.
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Executive summary
Nanoparticles characterization
•

The low positive charge of chitosan was not sufficient to increase the absorption
of the nanoparticles (NPs) through the intestinal epithelia. ζ potential of
poly(lactic-co-glycolic) acid (negative) and poly(lactic-co-glycolic) acid/
chitosan NPs (positive) were both very close to neutral at pH 7.

In vivo biodistribution

Author Manuscript

•

The highest NP presence was detected in the spleen (% dose/g tissue) and the
greatest mass of NPs was found in the intestine (mg).

•

Of the total dose of NPs orally administered (21 mg) over a period of 7 days, the
recovered amount was only 1.5 mg. Most NPs were excreted or were still in
circulation at the time of sampling.
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Figure 1.

Synthesis of poly(lactic-co-glycolic) acid-tetramethylrhodamine-5-isothiocyanate to be used
in the nanpparticle synthesis.
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Figure 2. Transmission electron microscope picture showing the spherical morphology of
poly(lactic-co-glycolic) acid and poly(lactic-co-glycolic) acid/chitosan nanoparticles
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(A) Poly(lactic-co-glycolic) acid and (B) poly(lactic-co-glycolic) acid/chitosan.
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Figure 3. Size and ζ potential change of poly(lactic-co-glycolic) acid and poly(lactic-co-glycolic)
acid/chitosan nanoparticles as a function of pH

(A) PLGA nanoparticles and (B) PLGA/Chi nanoparticles, indicating that PLGA NPs
maintained a stable size (~100 nm) and ζ potential [0, −2 mV] over the pHs tested, whereas
PLGA/Chi NPs increased in size from 150 nm to over 450 nm with a change of ζ potential
from 31 mV at acidic pHs to 0.5 mV at neutral pHs specific to the intestinal media.
NP: Nanoparticle; PLGA: Poly(lactic-co-glycolic) acid; PLGA/Chi: PLGA/chitosan.
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Figure 4. In vivo biodistribution of fluorescent nanoparticles
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The amount of fluorescent nanoparticle in each organ was determined on the basis of
standard curves; the results were expressed as % total dose/g tissue. (a–c) depict statistically
significant differences between organs for each treatment (p < 0.05). When PLGA and
PLGA/Chi nanoparticle treatments were compared, no statistical difference was found (p >
0.05).
PLGA: Poly(lactic-co-glycolic) acid; PLGA/Chi: PLGA/chitosan.
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Figure 5. Percentage of total dose of fluorescent poly(lactic-co-glycolic) acid and poly(lactic-coglycolic) acid/chitosan nanoparticles recovered in each analyzed organ

The highest dose of the orally delivered treatments was detected in the intestine for both
PLGA and PLGA/Chi nanoparticles, with no significant difference between the two
treatments.
PLGA: Poly(lactic-co-glycolic) acid; PLGA/Chi: PLGA/chitosan.
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Figure 6. Mass of PLGA and PLGA-Chi (mg) nanoparticles recovered in the organs tested (liver,
intestine, kidney, spleen, heart, lung and bran) after gavage daily for 7 days

The total mass of NPs recovered was 1.38 mg for PLGA NPs and 1.23 mg PLGA/Chi NPs
out of the 21 mg NPs orally administered by daily gavage of 3 mg NPs to the F344 rats over
7 days.
NP: Nanoparticle; PLGA: Poly(lactic-co-glycolic) acid; PLGA/Chi: PLGA/chitosan.
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Polymeric nanoparticle characteristics.
Diameter (nm)

PDI

ζ (mV)

†
PVA (%)

PLGA

112 ± 9

0.112 ± 0.017

− 2.1 ± 0.8

23.7 ± 1.2

PLGA/Chi

134 ± 8

0.250 ± 0.058

+ 4.9 ± 2.0

24 ± 1.5

PDI: Polydispersity index; PLGA: Poly(lactic-co-glycolic) acid; PLGA/Chi: PLGA/chitosan.
†

The PVA (%) was estimated relative to the initial amount used in the polymeric nanoparticles synthesis. n = 3 for all measurements.
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